COVID-19: Relief Efforts in China

Since the outbreak of the Coronavirus disease in China in late January, Boehringer Ingelheim has quickly decided to make a number of donations, including RMB 1 million cash donation to the China Red Cross Foundation to purchase protective materials for hospitals in Wuhan and other cities in Hubei Province to help local front-line medical staff involved in the fight against the epidemic to treat patients more safely.

During the Chinese New Year period, Boehringer Ingelheim purchased 100,000 protective masks worth more than RMB 2 million to be sent from Germany to hospitals in Wuhan for protection of medical workers.

In addition, Boehringer Ingelheim donated relevant medicines worth RMB 4 million to help treating patients affected COVID-19. 

Boehringer Ingelheim China is leveraging its research and expertise in antibody and small molecule research to support and expedite local partners’ ongoing efforts. The company is working with the University of Peking to investigate a potential antiviral effect of ambroxol hydrochloride. Boehringer Ingelheim plans to work with Chinese partners to treat the Acute Respiratory Distress Symptom (ARDS) caused by COVID-19. The company is also planning to sponsor an epidemiology study initiated by Chinese researchers to explore real-world efficacy and safety of ambroxol hydrochloride for treating COVID-19.